EMS
Brazilian pharmaceutical manufacturer with a portfolio spanning generics, prescription, and OTC medicines.
Founded
1964Brazilian pharmaceutical manufacturer with a portfolio spanning generics, prescription, and OTC medicines.
EMS organizes its business into prescription, generics, branded-medicine, OTC and hospital units, manufacturing products for practically all medical specialties with more than 1,100 presentations — from anti-inflammatories, antibiotics and antidiabetics to consumer brands such as Dermacyd, Multigrip, Caladryl, Lacday and Bálsamo Bengué.
The company's newest product platform is injectable GLP-1 metabolic therapy: OLIRE, LIRUX and the newly approved OZIVY semaglutide pen, all manufactured in Brazil by chemical synthesis and classified by Anvisa as new medicines rather than generics or biosimilars. In 2026 EMS also folded Fresenius Kabi's injectable-medicines portfolio and the Anápolis (GO) plant into its hospital business.
EMS is positioning itself around the fast-expanding GLP-1 metabolic-therapy market: Brazilian GLP-1 category sales reached about R$14.6 billion after 110% growth and are projected at roughly R$50 billion by 2030, and EMS' semaglutide pen OZIVY — approved by Anvisa in May 2026 as the first fully national GLP-1 analog — was announced at an introductory price near R$300 per month.
Beyond GLP-1, EMS agreed in May 2026 to acquire Sanofi's Medley generics unit for approximately R$3.6 billion, which would lift its Brazilian generics share to an estimated 30% pending antitrust approval, and in June 2026 it added Fresenius Kabi's injectables portfolio and the Anápolis plant. Grupo NC CEO Thiago Tavares frames the Medley deal as a platform for acquisitions in Mexico and Eastern Europe and entry into the US market after 2030.
EMS has led the Brazilian pharmaceutical market for roughly two decades and holds the country's largest medicine portfolio, with more than 1,100 product presentations spanning prescription, generics, branded, OTC and hospital units. The company has headed the Brazilian generics segment since 2013, reports a presence in more than 95% of national points of sale, and maintains installed production capacity above one billion units per year.
EMS operates what it describes as Latin America's most technologically advanced pharmaceutical R&D center, with more than 800 researchers and approximately 100 patents granted or pending in Brazil and abroad. In 2024 it inaugurated Brazil's first peptide factory — an investment above R$1.2 billion capable of producing up to 40 million GLP-1 pens a year — and it was the first Brazilian pharmaceutical company to sell medicines into Europe, exporting to more than 55 countries.
EMS' expansion depends on Brazilian regulatory and antitrust milestones: the R$3.6 billion Medley acquisition still awaits CADE clearance, GLP-1 launches depend on Anvisa registrations and CMED pricing procedures, and the company's own vice-president has publicly described regulation as an obstacle for the national pharmaceutical industry.
The company also carries geographic concentration risk: its revenue base is overwhelmingly domestic and retail-prescription oriented, and its international expansion — entering the US generics market only after 2030, with Mexico and Eastern Europe as nearer-term targets — remains at an early stage relative to global competitors.
EMS built its market position on affordable generics and similar medicines, and it states that OZIVY will carry a price that enables expanded access with a deliberately competitive market entry — reportedly around R$300 per month during a patient's first three months of therapy. Its GLP-1 pens are produced domestically by chemical synthesis, a cost structure EMS uses to undercut imported reference products.
In portfolio acquisitions, EMS committed to keeping factory prices and maximum consumer prices unchanged during the Fresenius Kabi Brasil injectables transfer, and its consumer brands such as Dermacyd, Multigrip and Lacday follow a mass-market self-care pricing approach distributed through its nationwide retail-pharmacy presence.